Gene expression profiling and clinical outcome in breast cancer

被引:42
作者
Bertucci, Francois [1 ]
Finetti, Pascal [1 ]
Cervera, Nathalie [1 ]
Maraninchi, Dominique [1 ]
Viens, Patrice [1 ]
Birnbaum, Daniel [1 ]
机构
[1] Univ Mediterranee, Inst J Paoli I Calmettes, INSERM UMR 599, Ctr Rech Cancerol Marseille,Dept Oncol Med, F-13273 Marseille 9, France
关键词
D O I
10.1089/omi.2006.10.429
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pathologic and clinical heterogeneity of breast cancer reflects the poorly documented, complex, and combinatory molecular basis of the disease and is in part responsible for therapeutic failures. The DNA microarray technique allows the analysis of RNA expression of several thousands of genes simultaneously in a sample. There are multiple potential applications of the technique in cancer research. A number of recent studies have shown the promising role of gene expression profiling in breast cancer by identifying new prognostic subclasses unidentifiable by conventional parameters and new prognostic and/or predictive gene signatures, whose predictive impact is superior to conventional histoclinical prognostic factors. In this review we describe current use of DNA microarrays in the prognosis of breast cancer. We also discuss issues that need to be addressed in the near future to allow the method to reach its full potential.
引用
收藏
页码:429 / 443
页数:15
相关论文
共 86 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt [J].
Ahmed, AA ;
Brenton, JD .
BREAST CANCER RESEARCH, 2005, 7 (03) :96-99
[3]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[4]   Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene [J].
Albertson, DG ;
Ylstra, B ;
Segraves, R ;
Collins, C ;
Dairkee, SH ;
Kowbel, D ;
Kuo, WL ;
Gray, JW ;
Pinkel, D .
NATURE GENETICS, 2000, 25 (02) :144-146
[5]   Reproducibility of gene expression signature-based predictions in replicate experiments [J].
Anderson, K ;
Hess, KR ;
Kapoor, M ;
Tirrel, S ;
Courtemanche, J ;
Wang, BL ;
Wu, Y ;
Gong, Y ;
Hortobagyi, GN ;
Symmans, WF ;
Pusztai, L .
CLINICAL CANCER RESEARCH, 2006, 12 (06) :1721-1727
[6]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[7]  
Bastholt L, 2005, J CLIN ONCOL, V23, p507S
[8]   Gene expression profiling identifies molecular subtypes of inflammatory breast cancer [J].
Bertucci, F ;
Finetti, P ;
Rougemont, J ;
Charafe-Jauffret, E ;
Cervera, N ;
Tarpin, C ;
Nguyen, C ;
Xerri, L ;
Houlgatte, M ;
Jacquemier, J ;
Viens, P ;
Birnbaum, D .
CANCER RESEARCH, 2005, 65 (06) :2170-2178
[9]   Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy [J].
Bertucci, F ;
Finetti, P ;
Rougemont, J ;
Charafe-Jauffret, E ;
Nasser, V ;
Loriod, W ;
Camerlo, J ;
Tagett, R ;
Tarpin, C ;
Houvenaeghel, G ;
Nguyen, C ;
Maraninchi, D ;
Jacquemier, J ;
Houlgatte, R ;
Birnbaum, D ;
Viens, P .
CANCER RESEARCH, 2004, 64 (23) :8558-8565
[10]   Identification and validation of an ERBB2 gene expression signature in breast cancers [J].
Bertucci, F ;
Borie, N ;
Ginestier, C ;
Groulet, A ;
Charafe-Jauffret, E ;
Adélaïde, J ;
Geneix, J ;
Bachelart, L ;
Finetti, P ;
Koki, A ;
Hermitte, F ;
Hassoun, J ;
Debono, S ;
Viens, P ;
Fert, V ;
Jacquemier, J ;
Birnbaum, D .
ONCOGENE, 2004, 23 (14) :2564-2575